Lartruvo takes a big step back as Lilly aims to beef up in cancer by Eric Sagonowsky Friday, January 18, 2019 Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.
Lilly lays out sunny 2019 forecast driven by growth of new meds by Arlene Weintraub Wednesday, December 19, 2018 Lilly provided a forecast for next year that beat analysts’ expectations—welcome news as blockbuster Cialis faces generic rivals.
Lilly weighs $200M-plus sale of China drug portfolio: report by Arlene Weintraub Friday, November 16, 2018 Eli Lilly may have found one way to raise some quick cash to pour into its portfolio of growth prospects.
With Cialis under pressure, Lilly's new launches step up by Eric Sagonowsky Tuesday, November 6, 2018 Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.
Teva launches generic Cialis as Lilly braces for loss of ED blockbuster by Arlene Weintraub Friday, September 28, 2018 Sales of Lilly's Cialis are set to fall from $2.3 billion a year to $55 million, pressuring the company to forge new lucrative markets.
Lilly's ED med Cialis sees sales suffer in wake of Viagra generics by Tracy Staton Wednesday, January 31, 2018 Eli Lilly's newer drugs are pumping out sales, especially its lead growth driver Trulicity, a diabetes drug. So much so, the company hiked its 2018 guidance.
Pfizer's Viagra finally set to face cheaper competition by Eric Sagonowsky Thursday, December 7, 2017 All these years after its initial approval, Pfizer's little blue pill Viagra is coming to the end of its patent life.
